Insider Selling: Nature’s Sunshine Products, Inc. (NASDAQ:NATR) Major Shareholder Sells $17,056.00 in Stock

Nature’s Sunshine Products, Inc. (NASDAQ:NATR) major shareholder Fosun Pharmaceutical Shanghai sold 1,300 shares of Nature’s Sunshine Products stock in a transaction on Monday, October 14th. The stock was sold at an average price of $13.12, for a total value of $17,056.00. Following the sale, the insider now directly owns 66,467 shares of the company’s stock, valued at $872,047.04. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Fosun Pharmaceutical Shanghai also recently made the following trade(s):

• On Thursday, October 10th, Fosun Pharmaceutical Shanghai sold 3,000 shares of Nature’s Sunshine Products stock. The shares were sold at an average price of $13.39, for a total transaction of $40,170.00.
• On Tuesday, October 8th, Fosun Pharmaceutical Shanghai sold 1,800 shares of Nature’s Sunshine Products stock. The stock was sold at an average price of $13.13, for a total transaction of $23,634.00.
• On Tuesday, October 1st, Fosun Pharmaceutical Shanghai sold 1,399 shares of Nature’s Sunshine Products stock. The stock was sold at an average price of $13.54, for a total transaction of $18,942.46.

Nature’s Sunshine Products Price Performance

Shares of NASDAQ:NATR opened at $13.34 on Friday. Nature’s Sunshine Products, Inc. has a 1 year low of $10.81 and a 1 year high of $21.72. The stock has a market capitalization of $249.86 million, a price-to-earnings ratio of 15.69 and a beta of 0.87. The company’s 50 day simple moving average is $13.33 and its 200 day simple moving average is $15.45.

Nature’s Sunshine Products (NASDAQ:NATR) last issued its earnings results on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.18). Nature’s Sunshine Products had a net margin of 3.50% and a return on equity of 9.79%. The business had revenue of $110.55 million during the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its holdings in shares of Nature’s Sunshine Products by 4.7% in the second quarter. Dimensional Fund Advisors LP now owns 786,966 shares of the company’s stock worth $11,860,000 after acquiring an additional 34,996 shares during the last quarter. Paradigm Capital Management Inc. NY grew its holdings in shares of Nature’s Sunshine Products by 26.8% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 695,079 shares of the company’s stock valued at $10,475,000 after purchasing an additional 146,879 shares during the last quarter. Vanguard Group Inc. increased its position in Nature’s Sunshine Products by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 659,686 shares of the company’s stock worth $13,702,000 after purchasing an additional 3,792 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Nature’s Sunshine Products by 1.9% in the 2nd quarter. Renaissance Technologies LLC now owns 559,797 shares of the company’s stock valued at $8,436,000 after purchasing an additional 10,700 shares during the last quarter. Finally, Wasatch Advisors LP boosted its position in Nature’s Sunshine Products by 20.6% in the first quarter. Wasatch Advisors LP now owns 518,161 shares of the company’s stock valued at $10,762,000 after buying an additional 88,433 shares in the last quarter. Institutional investors own 79.40% of the company’s stock.

Analyst Upgrades and Downgrades

NATR has been the subject of a number of analyst reports. StockNews.com upgraded shares of Nature’s Sunshine Products from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 10th. Canaccord Genuity Group initiated coverage on Nature’s Sunshine Products in a report on Friday, September 13th. They issued a “buy” rating and a $18.00 price objective for the company. Canaccord Genuity Group started coverage on Nature’s Sunshine Products in a report on Friday, September 13th. They set a “buy” rating and a $18.00 target price on the stock. Finally, DA Davidson decreased their price target on Nature’s Sunshine Products from $23.00 to $21.00 and set a “buy” rating on the stock in a research report on Monday, August 12th.

Nature’s Sunshine Products Company Profile

Nature’s Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.